Exascale Labs Holdings Inc.
XLAB Nasdaq Services-Prepackaged Software Financials FY2025–FY2026
Last close · Oct 23, 2026
$3.35
28.9%What Exascale Labs Holdings Inc. does
No business description yet.
- Legal name
- Exascale Labs Holdings Inc.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Sep 28, 2026
- Accession · CIK
- 0001829126-26-010462
0002109869
Revenue and margins
Exascale Labs Holdings Inc. had $14.8M of revenue in fiscal 2026, up 111.3% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2026, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Exascale Labs Holdings Inc. returned — to shareholders in fiscal 2026. The diluted share count rose 0.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably Exascale Labs Holdings Inc. can carry it.
| Fiscal year end | FY25 | FY26 |
|---|---|---|
| Cash and short-term investments | $4.2M | $2.7M |
| Current ratio | 0.4x | 0.2x |
| Quick ratio | 0.4x | 0.2x |
| Total assets | $7.3M | $6.7M |
| Total liabilities | $20.3M | $31.9M |
| Shareholders' equity | −$13.0M | −$25.2M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY25 | FY26 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✕ |
| Share count didn't rise | — | ✓ |
| Gross margin rose | — | ✓ |
| Revenue rose relative to assets | — | ✓ |
| F-score | — / 3 | 4 / 8 |
| Accruals ratio | −90.8% | −133.9% |
| Altman Z'' | −21.01 | −42.66 |
2 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY25 | FY26 |
|---|---|---|
| Income statement | ||
| Revenue | $7.0M | $14.8M |
| Gross profit | $1.1M | $2.4M |
| Research and development | $2.8M | $5.5M |
| Operating income | −$3.0M | −$4.8M |
| Pretax income | −$7.7M | −$12.2M |
| Net income | −$7.7M | −$12.2M |
| Net income to common | −$7.7M | −$12.2M |
| Diluted EPS | −$5,106.44 | −$8,108.26 |
| Diluted shares | 0.00B | 0.00B |
| Cash flow | ||
| Cash from operations | −$1.0M | −$2.8M |
| Capital expenditure | $0.0M | — |
| Free cash flow | −$1.0M | — |
| Depreciation and amortization | $0.0M | $0.0M |
| Stock-based compensation | $0.2M | $0.0M |
| Balance sheet | ||
| Cash and short-term investments | $4.2M | $2.7M |
| Current assets | $7.3M | $6.5M |
| Current liabilities | $20.3M | $31.9M |
| Property and equipment, net | $0.0M | $0.0M |
| Total assets | $7.3M | $6.7M |
| Total liabilities | $20.3M | $31.9M |
| Shareholders' equity | −$13.0M | −$25.2M |
| Margins | ||
| Gross margin | 15.8% | 16.3% |
| Operating margin | −43.4% | −32.4% |
| EBITDA margin | −43.3% | −32.3% |
| Net margin | −109.2% | −82.1% |
| FCF margin | −14.4% | — |
| Returns | ||
| Return on capital employed | 23.4% | 19.1% |
| Return on assets | −104.6% | −173.1% |
| Growth | ||
| Revenue growth | — | 111.3% |
| Share count change | — | 0.0% |
| Financial health | ||
| Current ratio | 0.4x | 0.2x |
| Quick ratio | 0.4x | 0.2x |
| Capital allocation | ||
| Capex / revenue | 0.0% | — |
| Stock comp / revenue | 2.2% | 0.0% |
| Quality scores | ||
| Piotroski F-score | — | 4.0 |
| Altman Z'' | −21.0 | −42.7 |
| Accruals ratio | −90.8% | −133.9% |
Source: SEC EDGAR XBRL filings (CIK 0002109869). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.